These results suggested decreased level of TRIM37 assist in elevating the efficacy of anti-tumor therapy, indicating that TRIM37 was one potential therapeutic target for clinical treatment of T-ALL. This evidence concerns the gene TRIM37 and acute lymphoblastic leukemia.